Abstract
Retrospective characterization of cell-cell relationships in the tumor microenvironment provides significantly better predictive power than PD-L1 expression, tumor mutational burden (TMB), or gene expression profiles. In this small study assessing the safety and possible efficacy of gemcitabine and pembrolizumab in immunotherapy-naïve patients with NSCLC who have received prior treatment, we investigated both standard and novel immune parameters on 16 enrolled patients. The combination of gemcitabine and pembrolizumab could be administered safely but did not demonstrate synergism compared with historical controls. Novel findings of this study are that elevated frequencies of Tregulatory cells near CD3 T cells at baseline was associated with improved outcome to treatment (p<0.05). Integrating this Treg / T cell relationship metric together with overall T cell density yielded a tumor inflammation score which correlated (p<0.002) with disease response. We postulate this is indicative of ongoing anti-cancer immune response. Additionally, while prior studies documented that IgG Ab responses to TAA can identify targets of a coordinated T and B cell response and evidence of immune surveillance, this study found that high autoantibody responses, while not statistically significant, trended towards a worse outcome (p=0.06). This suggests to us that tumors may have developed mechanisms to escape the immune response to these TAAs.
Competing Interest Statement
R. E. Sanborn reports: Grant funding for investigator-sponsored trial from AstraZeneca, Merck; Consulting fees: GlaxoSmithKline, AstraZeneca, Janssen Oncology, Macrogenics, Daiichi Sankyo, Sanofi, BeiGene, Gilead, Regeneron, Targeted Oncology, G1 Therapeutics, GE HealthCare, Amgen, Lilly Oncology; Honoraria for educational presentations, manuscripts: EMD Serono, Illumina, GameOn!, OncLive, Binay Foundation, APP Oncology, Masters in Thoracic Oncology S. M. Jensen reports grants from Bristol Myers Squibb and Akoya Biosciences. Christopher Paustian reports no conflicts of interest. Shu-Ching Chang reports no conflicts of interest. Eloy Vetto reports no conflicts of interest. Q. Vu reports no conflicts of interest. V. Rajamanickam reports no conflicts of interest. B. Bernard reports no conflicts of interest. Y. Koguchi reports research funding from Bristol Myers Squibb, GlaxoSmithKline, and Shimadzu corporation outside the submitted work. W. Redmond reports research support from: Bristol-Myers Squibb, Inhibrx, Veana Therapeutics, Shimadzu, Galecto, and CanWell Pharma. Patents/Licensing fees: Galectin Therapeutics. Scientific Advisory Boards: Vesselon, Medicenna, Veana Therapeutics. B. A. Fox reports grants from Bristol Myers Squibb, Akoya Biosciences, Merck, and Incyte during the conduct of the study, personal fees from UbiVac, Turnstone, and Pfizer, Calidi, and PrimeVax outside the submitted work.
Clinical Trial
NCT02422381
Funding Statement
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA provided pembrolizumab and financial support for study conduct.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol was reviewed and approved by the Institutional Review Board at Providence Portland Medical Center, and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
e-mail addresses: Rachel.Sanborn{at}providence.org, Shawn.Jensen{at}providence.org, Christopher.Paustian{at}providence.org, ShuChing_Chang{at}edwards.com, eloyvetto3{at}gmail.com, Quyen.Vu{at}providence.org Venkatesh.Rajamanickam{at}providence.org, Brady.Bernard{at}providence.org, Yoshinobu.Koguchi{at}providence.org, William.Redmond{at}providence.org, Bernard.Fox{at}providence.org
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos